NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Any Advanced Solid Tumors|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Small Cell Lung Cancer|Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|Ovarian Cancer
Interventions: DRUG: NT-I7|DRUG: Pembrolizumab
Sponsor: NeoImmuneTech